RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation
Open Access
- 7 June 2025
- journal article
- review article
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-30
Abstract
RNA modifications are crucial for post-transcriptional gene regulation. Research on RNA modifications has become a novel frontier of epitranscriptomics. Up to now, over 170 kinds of modifications have been identified on mRNA and diverse non-coding RNA. Three classes of proteins (writers, erasers, and readers) regulate the addition, removal, and identification of epigenetic marks, thus affecting RNA biological functions. Increasing evidence identifies the dysregulation of RNA modifications in different cancer types and the therapeutic potential of targeting RNA-modifying enzymes. The ability of RNA modifications to improve mRNA stability and translation efficacy and decrease immunogenicity has been exploited for the clinical use of mRNA cancer vaccines. This review aims to shed light on several vital cap, tail, and internal modifications of RNA with a focus on the connection between RNA epigenetic pathways and cancer pathogenesis. We further explore the clinical potential of RNA modifications as dynamic biomarkers for cancer diagnosis, prognosis, and therapeutic response prediction, addressing both technological challenges and translational opportunities. Finally, we analyze the limitations of current studies and discuss the research focus in the future.Keywords
Funding Information
- The graduate student independent exploration and innovation project of Central South University (1053320241337)
- Key Program of National Natural Science Foundation of China (82130090, U22A20329)
- Science Found for Creative Research Groups of the National Natural Science Foundation of China (82221002)
- the Natural Science Foundation of Hunan Province (2024JJ5578)
- The science and technology innovation Program of Hunan Province (2022RC3004)
- The Scientific Research Program of FuRong Laboratory (No.2023SK2095)
- the Central South University Research Programme of Advanced Interdisciplinary Studies (2023QYJC004)
This publication has 317 references indexed in Scilit:
- ALKBH5/YTHDF2‐mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylationClinical and Translational Medicine, 2023
- YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradationClinical and Translational Medicine, 2022
- Aberrant translation regulated by METTL1/WDR4‐mediated tRNA N7‐methylguanosine modification drives head and neck squamous cell carcinoma progressionCancer Communications, 2022
- METTL1‐m7G‐EGFR/EFEMP1 axis promotes the bladder cancer developmentClinical and Translational Medicine, 2021
- METTL1 promotes hepatocarcinogenesis via m7G tRNA modification‐dependent translation controlClinical and Translational Medicine, 2021
- RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potentialClinical and Translational Medicine, 2021
- A Light‐Controllable Chemical Modulation of m6A RNA MethylationAngewandte Chemie International Edition, 2021
- Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer CellsAdvanced Science, 2021
- RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2Hepatology, 2017
- METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N 6‐methyladenosine‐dependent primary MicroRNA processingHepatology, 2016